Seres Therapeutics (NASDAQ:MCRB - Free Report) had its target price decreased by Oppenheimer from $5.00 to $4.00 in a research report sent to investors on Thursday, Benzinga reports. Oppenheimer currently has an outperform rating on the biotechnology company's stock.
Separately, Chardan Capital decreased their target price on shares of Seres Therapeutics from $8.00 to $6.00 and set a buy rating for the company in a report on Wednesday.
Read Our Latest Stock Analysis on MCRB
Seres Therapeutics Stock Performance
Shares of NASDAQ MCRB traded up $0.28 during trading on Thursday, hitting $1.03. The company had a trading volume of 16,672,368 shares, compared to its average volume of 5,070,415. The company has a market cap of $155.54 million, a P/E ratio of -1.14 and a beta of 2.16. The business's 50-day moving average is $0.83 and its 200 day moving average is $1.06. Seres Therapeutics has a 52 week low of $0.54 and a 52 week high of $6.26.
Seres Therapeutics (NASDAQ:MCRB - Get Free Report) last announced its earnings results on Tuesday, March 5th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.40) by $0.08. The company had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.50 million. On average, research analysts expect that Seres Therapeutics will post -1.15 EPS for the current year.
Institutional Trading of Seres Therapeutics
Several institutional investors have recently made changes to their positions in the stock. Commonwealth Equity Services LLC acquired a new position in shares of Seres Therapeutics during the 3rd quarter worth $26,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Seres Therapeutics in the 1st quarter worth approximately $39,000. Tower Research Capital LLC TRC boosted its position in Seres Therapeutics by 668.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 38,091 shares of the biotechnology company's stock worth $53,000 after purchasing an additional 33,135 shares during the period. Arete Wealth Advisors LLC grew its holdings in Seres Therapeutics by 99.2% during the third quarter. Arete Wealth Advisors LLC now owns 24,900 shares of the biotechnology company's stock valued at $59,000 after purchasing an additional 12,400 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of Seres Therapeutics in the fourth quarter worth $73,000. 59.34% of the stock is currently owned by institutional investors and hedge funds.
Seres Therapeutics Company Profile
(
Get Free Report)
Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.
See Also
Before you consider Seres Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Seres Therapeutics wasn't on the list.
While Seres Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
